Preclinical efficacy in investigator's brochures: Stakeholders' views on measures to improve completeness and robustness.

In principle, more robust decision-making processes align with the interests of all stakeholders and with many current initiatives to increase the translatability of preclinical research and limit uninformative or ill-justified trials early in the development process. Further research should investigate measures that could be implemented to benefit all stakeholders.